Income Statement
ACURX PHARMACEUTICALS, INC.
ACXP
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
8.09 | 14.10 | 14.58 | 12.09 | 12.81 |
|
Research & Development
|
1.83 | 5.40 | 6.04 | 4.75 | 2.03 |
|
Selling, General & Administrative
|
6.26 | 8.70 | 8.53 | 7.34 | 10.78 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-8.09 | -14.10 | -14.58 | -12.09 | -12.81 |
|
Non-Operating Income
|
- | - | - | - | - |
|
Interest Income
|
0.13 | - | - | - | - |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | - | - |
|
Income Before Tax
|
- | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-7.97 | -14.10 | -14.58 | -12.09 | -12.75 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-8.09 | -14.10 | -14.58 | -12.09 | -12.81 |
|
Earnings Per Share (Basic)
|
-5.32 | -0.87 | -1.15 | -1.12 | -1.49 |
|
Diluted EPS
|
-5.32 | -0.87 | -1.15 | -1.12 | -1.49 |
|
Weighted Average Shares
|
1.50 | 16.16 | 12.67 | 10.82 | 8.54 |
|
Diluted Weighted Avg Shares
|
1.50 | 16.16 | 12.67 | 10.82 | 8.54 |
|
Comprehensive Income
|
- | - | - | - | - |